Should a serum free light-chain assay be ordered?

Should a Serum Free Light Chain Assay Be Ordered?

Yes, the serum free light chain (FLC) assay should be ordered as part of the initial diagnostic workup when evaluating for plasma cell disorders, including multiple myeloma and related conditions. 1, 2

Rationale for Ordering

The serum FLC assay, when combined with serum protein electrophoresis (SPEP) and serum immunofixation electrophoresis (SIFE), provides high sensitivity for screening and detecting plasma cell disorders 1. This combination is now standard practice and included in major guidelines from NCCN and international consensus statements.

Key Clinical Utilities

Diagnostic sensitivity: The FLC assay detects cases that would otherwise be missed:

• Approximately 15-20% of multiple myeloma patients have light chain-only disease that may not be adequately detected by serum protein electrophoresis alone 3, 2
• In the 2019 consensus guidelines, the FLC assay is described as a "critical test" for detecting unbound free light chains 4
• Studies demonstrate that many myeloma patients will be overlooked if only serum M-protein is measured 5

Prognostic value: The FLC assay provides important prognostic information across the spectrum of plasma cell disorders, including:

• Monoclonal gammopathy of undetermined significance (MGUS)
• Smoldering myeloma
• Active myeloma
• Light chain amyloidosis
• Solitary plasmacytoma 1

Monitoring capability: The assay enables quantitative monitoring of:

• Light chain amyloidosis patients
• Oligosecretory myeloma
• Patients previously classified as having non-secretory myeloma 1

Response assessment: The FLC ratio is required for documenting stringent complete response according to International Myeloma Working Group criteria 1, 2

Important Caveats and Interpretation

Renal Function Impact

Critical consideration: Renal impairment significantly affects FLC concentrations because free light chains are cleared by the kidneys 4.

• Normal FLC ratio: 0.26-1.65
• In severe renal impairment (CKD stage 5 or greater): ratio can rise to 0.34-3.10
• Even small declines in renal function impair clearance 4

Pitfall to avoid: False-positive results commonly occur in elderly patients with renal impairment when using standard reference intervals, leading to unnecessary investigations 6. Consider eGFR-stratified reference intervals for more accurate interpretation.

Assay-Specific Considerations

Know which assay your laboratory uses: At least two major assays exist (FreeLite and N Latex), and they are not interchangeable 4:

• Results are mathematically inconvertible between assays
• Effects of renal impairment differ between assays (N Latex less affected than FreeLite)
• The same assay must be used throughout a patient's monitoring 4
• If the first assay is negative but clinical suspicion remains high, consider checking with the alternative assay 4

When FLC Alone Is Insufficient

Do not order in isolation: Neither FLC nor SPEP should be performed alone when screening for monoclonal gammopathy 7. The combination approach prevents missed diagnoses.

Limitations:

• FLC assay cannot replace 24-hour urine protein electrophoresis for monitoring patients with measurable urinary M-proteins 1
• Serum immunofixation may be more helpful than FLC in diseases with intact monoclonal immunoglobulin (such as PGNMID) 4
• False positives occur with inflammatory disorders or renal impairment 7

Recommended Testing Algorithm

When evaluating for plasma cell disorders, order:

1. Serum studies:

   • Serum protein electrophoresis (SPEP)
   • Serum immunofixation electrophoresis (SIFE)
   • Serum free light chain assay with κ/λ ratio
   • Quantitative immunoglobulins (IgG, IgA, IgM)

2. Urine studies:

   • 24-hour urine for total protein
   • Urine protein electrophoresis (UPEP)
   • Urine immunofixation electrophoresis (UIFE)

3. Additional baseline labs:

   • Creatinine/eGFR (essential for FLC interpretation)
   • Beta-2 microglobulin
   • Calcium, albumin, CBC, LDH

This comprehensive approach maximizes diagnostic sensitivity while minimizing false-positive results when interpreted in the appropriate clinical context with attention to renal function 1, 4, 1, 2.